MacroGenics (MGNX) Competitors $1.58 -0.01 (-0.63%) Closing price 04:00 PM EasternExtended Trading$1.58 +0.00 (+0.06%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MGNX vs. BNTC, AVIR, IVA, AARD, OCGN, GOSS, ALT, GLUE, RNAC, and TKNOShould you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include Benitec Biopharma (BNTC), Atea Pharmaceuticals (AVIR), Inventiva (IVA), Aardvark Therapeutics (AARD), Ocugen (OCGN), Gossamer Bio (GOSS), Altimmune (ALT), Monte Rosa Therapeutics (GLUE), Cartesian Therapeutics (RNAC), and Alpha Teknova (TKNO). These companies are all part of the "pharmaceutical products" industry. MacroGenics vs. Its Competitors Benitec Biopharma Atea Pharmaceuticals Inventiva Aardvark Therapeutics Ocugen Gossamer Bio Altimmune Monte Rosa Therapeutics Cartesian Therapeutics Alpha Teknova Benitec Biopharma (NASDAQ:BNTC) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk. Which has more risk and volatility, BNTC or MGNX? Benitec Biopharma has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Do insiders & institutionals believe in BNTC or MGNX? 52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 1.3% of Benitec Biopharma shares are held by company insiders. Comparatively, 13.0% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is BNTC or MGNX more profitable? Benitec Biopharma has a net margin of 0.00% compared to MacroGenics' net margin of -36.23%. Benitec Biopharma's return on equity of -38.26% beat MacroGenics' return on equity.Company Net Margins Return on Equity Return on Assets Benitec BiopharmaN/A -38.26% -35.71% MacroGenics -36.23%-59.84%-23.45% Do analysts prefer BNTC or MGNX? Benitec Biopharma presently has a consensus price target of $23.83, indicating a potential upside of 72.83%. MacroGenics has a consensus price target of $5.71, indicating a potential upside of 261.66%. Given MacroGenics' higher probable upside, analysts clearly believe MacroGenics is more favorable than Benitec Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Benitec Biopharma 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20MacroGenics 0 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.40 Does the media refer more to BNTC or MGNX? In the previous week, Benitec Biopharma had 3 more articles in the media than MacroGenics. MarketBeat recorded 6 mentions for Benitec Biopharma and 3 mentions for MacroGenics. Benitec Biopharma's average media sentiment score of 0.36 beat MacroGenics' score of 0.34 indicating that Benitec Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MacroGenics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation and earnings, BNTC or MGNX? Benitec Biopharma has higher earnings, but lower revenue than MacroGenics. Benitec Biopharma is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBenitec Biopharma$80K4,524.84-$21.75M-$1.51-9.13MacroGenics$149.96M0.66-$66.97M-$0.89-1.78 SummaryBenitec Biopharma beats MacroGenics on 9 of the 17 factors compared between the two stocks. Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGNX vs. The Competition Export to ExcelMetricMacroGenicsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$100.31M$10.57B$5.56B$9.04BDividend YieldN/A2.08%5.25%4.03%P/E Ratio-1.7816.5627.1820.14Price / Sales0.6630.26440.78137.14Price / CashN/A22.8437.5058.41Price / Book0.853.758.085.60Net Income-$66.97M$235.43M$3.16B$248.43M7 Day Performance9.72%3.78%3.77%5.15%1 Month Performance-11.24%3.95%3.90%7.62%1 Year Performance-63.00%-9.49%34.22%21.56% MacroGenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGNXMacroGenics4.1369 of 5 stars$1.58-0.6%$5.71+261.7%-62.8%$100.31M$149.96M-1.78430BNTCBenitec Biopharma2.1687 of 5 stars$11.70+3.1%$23.83+103.7%+50.1%$297.94M$80K-7.7520News CoverageAnalyst ForecastHigh Trading VolumeAVIRAtea Pharmaceuticals3.1438 of 5 stars$3.60+4.3%$6.00+66.7%+17.9%$295.25MN/A-2.1870News CoverageHigh Trading VolumeIVAInventiva3.2604 of 5 stars$3.19+4.6%$10.40+226.0%+28.1%$291.77M$9.95M0.00100News CoverageAARDAardvark TherapeuticsN/A$13.52+1.0%$33.00+144.1%N/A$290.51MN/A0.0018OCGNOcugen1.0008 of 5 stars$0.97-1.4%$6.00+518.3%-37.4%$287.39M$4.05M-5.1180High Trading VolumeGOSSGossamer Bio3.7676 of 5 stars$1.23-1.6%$7.33+496.2%+13.3%$284.13M$114.70M-5.35180ALTAltimmune2.3183 of 5 stars$3.87+10.6%$19.00+391.0%-31.3%$283.87M$20K-3.0750News CoverageAnalyst ForecastGap DownHigh Trading VolumeGLUEMonte Rosa Therapeutics1.3618 of 5 stars$4.51-2.0%$15.33+240.0%+33.6%$282.95M$75.62M56.3890Positive NewsRNACCartesian Therapeutics2.016 of 5 stars$10.39-2.7%$41.25+297.0%-17.9%$277.19M$38.91M-0.2064News CoverageAnalyst ForecastTKNOAlpha Teknova3.0684 of 5 stars$4.91-3.9%$8.50+73.1%+329.3%$273.08M$37.74M-10.23240News Coverage Related Companies and Tools Related Companies Benitec Biopharma Alternatives Atea Pharmaceuticals Alternatives Inventiva Alternatives Aardvark Therapeutics Alternatives Ocugen Alternatives Gossamer Bio Alternatives Altimmune Alternatives Monte Rosa Therapeutics Alternatives Cartesian Therapeutics Alternatives Alpha Teknova Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGNX) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MGNX Stock Alerts